AptaTargets

aptatargets.com ↗ ·Madrid ·Series A

AptaTargets is a Madrid-based clinical-stage biopharmaceutical company developing therapeutic aptamers (nucleic-acid drugs) for acute inflammation-related diseases. Its lead candidate, ApTOLL, is a first-in-class TLR4-antagonist neuroprotectant for acute ischemic stroke that completed Phase Ib/IIa trials and was licensed to Merck. Founded in 2014 as a spin-out of Aptus Biotech, it has raised financing rounds backed by Caixa Capital Risc and Inveready.

Founded

2014

Founders

Total funds raised

€5M

SectorsBiotechnology, Clinical-stage pharmaceuticals, Aptamer therapeutics, Neurology / stroke treatment Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

David Segarra

Co-Founder & CEO

Mª Eugenia Zarabozo

Co-Founder & CFO

Global models 5

SomaLogic

United States · somalogic.com ↗

Pioneered the same SELEX aptamer-discovery technology platform, originally developing therapeutic and diagnostic aptamers before focusing on proteomics.

$400M+Comparable

Archemix

United States

Clinical-stage biotech that developed multiple therapeutic aptamer drug candidates across several disease areas, the closest historical analogue to AptaTargets' model.

$200M+Comparable

Eyetech Pharmaceuticals

United States

Developed Macugen, the first FDA-approved aptamer drug, following the same path of taking a therapeutic aptamer from discovery through clinical approval.

$150M+Comparable

NOXXON Pharma

Germany · www.noxxon.com ↗

European clinical-stage biotech developing proprietary nucleic-acid (Spiegelmer/aptamer) therapeutics, a direct European comparable to AptaTargets.

$100M+Comparable

Vitrisa Therapeutics

United States

VC-backed clinical-stage company developing therapeutic aptamers, mirroring AptaTargets' single-modality drug-development model.

$40MComparable